BACKGROUND:Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) have been shown to reduce cardiovascular mortality at a dose of ≈1 g/d. Studies using higher doses have shown evidence of reduced inflammation and improved endothelial function. Few studies have compared these doses. OBJECTIVE: The objective of this study was to compare the effects of a nutritional dose of EPA+DHA (0.85 g/d) with those of a pharmaceutical dose (3.4 g/d) on serum triglycerides, inflammatory markers, and endothelial function in healthy subjects with moderately elevated triglycerides. DESIGN: This was a placebo-controlled, double-blind, randomized, 3-period crossover trial (8 wk of treatment, 6 wk of washout) that compared the effects of 0.85 and 3.4 g EPA+DHA/d in 23 men and 3 postmenopausal women with moderate hypertriglyceridemia (150-500 mg/dL). RESULTS: The higher dose of EPA+DHA lowered triglycerides by 27% compared with placebo (mean ± SEM: 173 ± 17.5 compared with 237 ± 17.5 mg/dL; P = 0.002), whereas no effect of the lower dose was observed on lipids. No effects on cholesterol (total, LDL, and HDL), endothelial function [as assessed by flow-mediated dilation, peripheral arterial tonometry/EndoPAT (Itamar Medical Ltd, Caesarea, Israel), or Doppler measures of hyperemia], inflammatory markers (interleukin-1β, interleukin-6, tumor necrosis factor-α, and high-sensitivity C-reactive protein), or the expression of inflammatory cytokine genes in isolated lymphocytes were observed. CONCLUSION: The higher dose (3.4 g/d) of EPA+DHA significantly lowered triglycerides, but neither dose improved endothelial function or inflammatory status over 8 wk in healthy adults with moderate hypertriglyceridemia. The trial was registered at clinicaltrials.gov as NCT00504309.
RCT Entities:
BACKGROUND:Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) have been shown to reduce cardiovascular mortality at a dose of ≈1 g/d. Studies using higher doses have shown evidence of reduced inflammation and improved endothelial function. Few studies have compared these doses. OBJECTIVE: The objective of this study was to compare the effects of a nutritional dose of EPA+DHA (0.85 g/d) with those of a pharmaceutical dose (3.4 g/d) on serum triglycerides, inflammatory markers, and endothelial function in healthy subjects with moderately elevated triglycerides. DESIGN: This was a placebo-controlled, double-blind, randomized, 3-period crossover trial (8 wk of treatment, 6 wk of washout) that compared the effects of 0.85 and 3.4 g EPA+DHA/d in 23 men and 3 postmenopausal women with moderate hypertriglyceridemia (150-500 mg/dL). RESULTS: The higher dose of EPA+DHA lowered triglycerides by 27% compared with placebo (mean ± SEM: 173 ± 17.5 compared with 237 ± 17.5 mg/dL; P = 0.002), whereas no effect of the lower dose was observed on lipids. No effects on cholesterol (total, LDL, and HDL), endothelial function [as assessed by flow-mediated dilation, peripheral arterial tonometry/EndoPAT (Itamar Medical Ltd, Caesarea, Israel), or Doppler measures of hyperemia], inflammatory markers (interleukin-1β, interleukin-6, tumor necrosis factor-α, and high-sensitivity C-reactive protein), or the expression of inflammatory cytokine genes in isolated lymphocytes were observed. CONCLUSION: The higher dose (3.4 g/d) of EPA+DHA significantly lowered triglycerides, but neither dose improved endothelial function or inflammatory status over 8 wk in healthy adults with moderate hypertriglyceridemia. The trial was registered at clinicaltrials.gov as NCT00504309.
Authors: M L Burr; A M Fehily; J F Gilbert; S Rogers; R M Holliday; P M Sweetnam; P C Elwood; N M Deadman Journal: Lancet Date: 1989-09-30 Impact factor: 79.321
Authors: Jeffrey T Kuvin; Ayan R Patel; Kathleen A Sliney; Natesa G Pandian; Jacob Sheffy; Robert P Schnall; Richard H Karas; James E Udelson Journal: Am Heart J Date: 2003-07 Impact factor: 4.749
Authors: Emelia J Benjamin; Martin G Larson; Michelle J Keyes; Gary F Mitchell; Ramachandran S Vasan; John F Keaney; Birgitta T Lehman; Shuxia Fan; Ewa Osypiuk; Joseph A Vita Journal: Circulation Date: 2004-02-10 Impact factor: 29.690
Authors: J Dyerberg; D C Eskesen; P W Andersen; A Astrup; B Buemann; J H Christensen; P Clausen; B F Rasmussen; E B Schmidt; T Tholstrup; E Toft; S Toubro; S Stender Journal: Eur J Clin Nutr Date: 2004-07 Impact factor: 4.016
Authors: Tobias Pischon; Susan E Hankinson; Gökhan S Hotamisligil; Nader Rifai; Walter C Willett; Eric B Rimm Journal: Circulation Date: 2003-06-23 Impact factor: 29.690
Authors: Melinda S Schaller; Greg J Zahner; Warren J Gasper; William S Harris; Michael S Conte; Nancy K Hills; S Marlene Grenon Journal: J Clin Lipidol Date: 2017-06-24 Impact factor: 4.766
Authors: Eliza Miller; Gunveen Kaur; Amy Larsen; Su Peng Loh; Kaisa Linderborg; Harrison S Weisinger; Giovanni M Turchini; David Cameron-Smith; Andrew J Sinclair Journal: Eur J Nutr Date: 2012-06-23 Impact factor: 5.614
Authors: Michael R Flock; Ann C Skulas-Ray; William S Harris; Trent L Gaugler; Jennifer A Fleming; Penny M Kris-Etherton Journal: Prostaglandins Leukot Essent Fatty Acids Date: 2014-07-17 Impact factor: 4.006
Authors: Claire E Berryman; Jessica A Grieger; Sheila G West; Chung-Yen O Chen; Jeffrey B Blumberg; George H Rothblat; Sandhya Sankaranarayanan; Penny M Kris-Etherton Journal: J Nutr Date: 2013-04-24 Impact factor: 4.798
Authors: Katherine A Sauder; Ann C Skulas-Ray; Tavis S Campbell; Jillian A Johnson; Penny M Kris-Etherton; Sheila G West Journal: Psychosom Med Date: 2013-04-16 Impact factor: 4.312